CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com
Biocon Biologics  /  Investors

OVERVIEW

Biocon Biologics has raised ~USD 330 million from marquee private equity investors such as True North, Tata Capital, Goldman Sachs and ADQ.

The first private equity infusion of USD 75 million was made by Activ Pine LLP, an affiliate of True North Fund in January 2020. Activ Pine’s equity infusion was for a 2.44% stake at an equity valuation of USD 3 billion* on a pre-money basis.

In July 2020, Tata Capital Growth Fund invested Rs 225 Crore (~USD 30 million) for a 0.85% stake, valuing Biocon Biologics at an equity valuation of Rs 26,250 Crore (~USD 3.5 billion*).

Goldman Sachs issued Optionally Convertible Debentures (OCD) worth Rs 1,125 Crore (~USD 150 million) at a post-money equity valuation of USD 3.94 billion* in November 2020.

Abu Dhabi-based ADQ invested Rs 555 crore (~USD 75 million) for a 1.80% stake, valuing Biocon Biologics at a post-money valuation of ~USD 4.1 billion* in January 2021.

These investments validate Biocon Biologics’ science, scale, scope, strategy, and business prospects. It also reflects a high level of conviction in Biocon Biologics’ position as a global frontrunner in biosimilars which leverages its large-scale manufacturing capabilities to shift the access paradigm for these life-saving therapies.

Biocon Biologics has taken a landmark decision to acquire the global biosimilars business of its long-term partner Viatris in a ‘cash and stock’ deal. Viatris will receive a consideration of up to USD 3.335 billion, including cash up to USD 2.335 billion and Compulsorily Convertible Preference Shares (CCPS) in Biocon Biologics valued at USD 1 billion, equivalent to an equity stake of at least 12.9% on a fully-diluted basis.

Biocon Biologics had entered into a strategic alliance with Serum Institute Life Sciences (SILS) for vaccines and infectious disease antibodies in September 2021. Under the terms of the agreement, Biocon Biologics will offer ~15% stake to SILS, at a post-money valuation of ~USD 4.9 billion*.

*Calculated as on the date of signing of the deal

Biocon Biologics Limited (BBL) is a subsidiary of Biocon Limited, which operates its biosimilars business through BBL. The company develops high-quality and affordable biosimilars that can expand access to cutting-edge therapeutics for patients globally at its R&D sites in Bengaluru and Chennai (India). These are manufactured at scale for both developed and emerging markets in Bengaluru (India) and Johor (Malaysia). BBL’s products are marketed globally through a hybrid commercial model, wherein the company has direct commercial presence in a few countries and in others, we leverage partners such as Viatris.

As BBL is yet to be publicly listed, the share information below refers to the parent company Biocon Limited. To know more, please visit the Investors section of Biocon Limited.

Biocon Limited Investors Page

BIOCON LIMITED SHARE PRICE INFORMATION

  
Share